Haleon plc (NYSE:HLN) Shares Sold by Wallace Advisory Group LLC

Wallace Advisory Group LLC reduced its position in shares of Haleon plc (NYSE:HLN) by 32.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 11,929 shares of the company’s stock after selling 5,620 shares during the period. Wallace Advisory Group LLC’s holdings in Haleon were worth $126,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Fortitude Family Office LLC purchased a new position in shares of Haleon during the third quarter valued at approximately $28,000. Versant Capital Management Inc grew its stake in Haleon by 2,029.1% in the 4th quarter. Versant Capital Management Inc now owns 3,513 shares of the company’s stock worth $34,000 after acquiring an additional 3,348 shares during the period. Toronto Dominion Bank raised its holdings in Haleon by 3,470.0% in the 3rd quarter. Toronto Dominion Bank now owns 3,570 shares of the company’s stock valued at $38,000 after acquiring an additional 3,470 shares during the last quarter. Prospera Private Wealth LLC purchased a new position in shares of Haleon during the 3rd quarter worth $57,000. Finally, BOKF NA boosted its holdings in shares of Haleon by 68.8% during the second quarter. BOKF NA now owns 6,972 shares of the company’s stock worth $58,000 after purchasing an additional 2,842 shares during the last quarter. 6.67% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the company. Sanford C. Bernstein lowered Haleon from an “outperform” rating to a “market perform” rating in a research note on Wednesday, January 8th. Morgan Stanley downgraded shares of Haleon from an “overweight” rating to an “equal weight” rating in a research note on Friday, January 10th. Finally, UBS Group raised shares of Haleon to a “strong-buy” rating in a research report on Tuesday, October 1st. Three analysts have rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Haleon presently has a consensus rating of “Moderate Buy” and an average target price of $10.95.

Haleon Price Performance

Shares of Haleon stock opened at $9.02 on Wednesday. The business’s fifty day moving average price is $9.58 and its 200 day moving average price is $9.69. Haleon plc has a twelve month low of $7.89 and a twelve month high of $10.80. The company has a current ratio of 0.84, a quick ratio of 0.58 and a debt-to-equity ratio of 0.44. The stock has a market capitalization of $40.83 billion, a P/E ratio of 26.53, a PEG ratio of 2.95 and a beta of 0.29.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.